13 patents
Utility
Novel Proinsulin Glargine and Method for Preparing Insulin Glargine Therefrom
14 Sep 23
The present invention discloses novel proinsulin glargine and method for for preparing insulin glargine therefrom.
Chuangen TANG, Jing WANG, Shangshu PAN, Xiaoyang FAN, Xiaorui LIU, Song CHEN, Haoning ZHANG
Filed: 10 Mar 23
Utility
Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted Delivery
31 Aug 23
The present disclosure generally pertains to a medical device and more particularly, a metered-dose inhaler (“MDI”) actuator capable of a targeted delivery of fine API particles having particle diameters of about 1.1 μm or less to a portion of a patient's lungs where alveoli are located.
Jack Yongfeng Zhang, Mary Zi-ping Luo, Ying Wang, Yi Xia, Jie Fei Ding, Selina Su, Qingxia Han
Filed: 21 Apr 21
Utility
Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of Pharmaceuticals
17 Aug 23
The present disclosure introduces safe and effective pharmaceutical formulations for intranasal delivery.
Jack Yongfeng Zhang, Mary Zi-ping Lou, Jie Fei Ding, Aili Bo
Filed: 3 May 21
Utility
Small angle x-ray scattering methods for characterizing the iron core of iron carbohydrate colloid drug products
15 Aug 23
The present disclosure introduces methods for characterizing iron core carbohydrate colloid drug products, such as iron sucrose drug products.
Jack Yongfeng Zhang, Mary Zi-Ping Luo, Thang Kien Chiu, Anthony Marrs, Selina Su
Filed: 4 May 21
Utility
Injectable Epinephrine Formulations Demonstrating Active Pharmaceutical Ingredient (Api) Retention Over Time
4 May 23
Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months.
Jack Yongfeng Zhang, Mary Zi-ping Luo, Fonda Su, Marvin Lin, Jie Fei Ding, Justin Jun Wei, Wenbo Yu, Rong Zhou
Filed: 28 Oct 22
Utility
Stable Injectable Epinephrine Formulations Including a Metal-chelating Agent
4 May 23
Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months.
Jack Yongfeng Zhang, Mary Zi-ping Luo, Fonda Su, Marvin Lin, Jie Fei Ding, Justin Jun Wei, Wenbo Yu, Rong Zhou
Filed: 28 Oct 22
Utility
Small Angle X-ray Scattering Methods for Characterizing the Iron Core of Iron Carbohydrate Colloid Drug Products
20 Apr 23
The present disclosure introduces methods for characterizing iron core carbohydrate colloid drug products, such as iron sucrose drug products.
Jack Yongfeng ZHANG, Mary Zi-Ping LUO, Thang Kien CHIU, Anthony MARRS, Selina SU
Filed: 4 May 21
Utility
NMR Methods for Characterizing Iron Sucrose
20 Apr 23
The present disclosure provides NMR relaxation methods for characterizing iron carbohydrate drug products.
Jack Yongfeng ZHANG, Mary Zi-Ping LUO, Jie Fei DING, Justin Jun WEI, Richard BAO
Filed: 4 May 21
Utility
Injectable Epinephrine Formulations Demonstrating Stability Over Time
9 Mar 23
Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months.
Jack Yongfeng Zhang, Mary Zi-ping Luo, Fonda SU, Marvin Lin, Jie Fei Ding, Justin Jun Wei, Wenbo Yu, Rong Zhou
Filed: 28 Oct 22
Utility
Highly purified recombinant human insulin (RHI) API and methods of producing the same
13 Dec 22
Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.
Jie Fei Ding, Aili Bo, Jack Yongfeng Zhang, Mary Zi-ping Luo, Zhongli Bao
Filed: 25 Sep 19
Utility
High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
20 Sep 22
A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%.
Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
Filed: 28 Aug 19
Utility
Highly Purified Recombinant Human Insulin (Rhi) Api and Methods of Producing the Same
8 Jul 20
Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.
Jie Fei Ding, Aili Bo, Jack Yongfeng Zhang, Mary Zi-ping Luo, Zhongli Bao
Filed: 24 Sep 19
Utility
High-purity Inhalable Particles of Insulin and Insulin Analogues, and High-efficiency Methods of Manufacturing the Same
25 Dec 19
A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%.
Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
Filed: 27 Aug 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first